LauraSimonsGrahamMD

Oncology • Aurora, CO

Physician

Join to view full profile

Dr. Graham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Graham's full profile

Already have an account?

Office
1665 Aurora Ct
Aurora, CO 80045
Phone+1 720-848-0000

Summary

Dr. Laura Graham is an oncologist in Aurora, CO and is affiliated with UW Medicine/University of Washington Medical Center. She received her medical degree from Rush Medical College of Rush University Medical Center and has been in practice 1 year. She is experienced in urinary tract cancer and internal medicine/oncology.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2018 - 2021
University of WashingtonResidency, Internal Medicine, 2015 - 2018
Rush Medical College of Rush University Medical CenterClass of 2015
University of ChicagoBA, Biological Sciences, 2005 - 2009

Certifications & Licensure

CO State Medical License 2021 - 2025
WA State Medical License 2015 - 2022
ID State Medical License 2017 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Inductee Alpha Omega Alpha Honor Medical Society

Publications & Presentations

PubMed

57 citations
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura S Graham, Kalyan Banda, Alba Torres, Brett S. Carver, Yu Chen
Investigational New Drugs. 2018-03-06
62 citations
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Laura S. Graham, Bruce Montgomery, Heather H. Cheng, Evan Y. Yu, Peter S. Nelson
Plos One. 2020-05-26
9 citations
Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
Laura S. Graham, Colin C. Pritchard, Michael T. Schweizer
Clinical Cancer Research. 2021-09-27

Lectures

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018